Longeveron Chief Science Officer and Chief Medical Officer Selected as Speakers at the Global CardioVascular Clinical Trialists (CVCT) Forum
Longeveron Inc. - common stock (LGVN)
Company Research
Source: GlobeNewswire
MIAMI, Fla., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced that its Chief Science Officer, Dr. Joshua Hare, and Chief Medical Officer, Dr. Nataliya Agafonova, will speak on multiple panel discussions at the Global CardioVascular Clinical Trialists (CVCT) Forum taking place December 8-10, 2025 in Washington, D.C. The CVCT Forum seeks to promote rigorous evidence generation and accelerate the global impact of cardiovascular clinical trials. Panel Discussions – December 8, 2025 Cell Therapy Heart Failure Trials – Cells Deliver and Disease Specific StrategiesIs Cell Delivery Route Important?Intravenous Delivery of Cells/Cell Products: The Magic Bullet? Dr. Joshua Hare What Type of Cells?Mesenchymal Stem Cell Therapy for Dilated Cardiomyopathy: Lessons from POSEIDON and the PATH AHEAD – Dr. Joshua Hare How
Show less
Read more
Impact Snapshot
Event Time:
LGVN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LGVN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LGVN alerts
High impacting Longeveron Inc. - common stock news events
Weekly update
A roundup of the hottest topics
LGVN
News
- Longeveron Chief Science Officer and Chief Medical Officer Selected as Speakers at the Global CardioVascular Clinical Trialists (CVCT) Forum [Yahoo! Finance]Yahoo! Finance
- Longeveron Granted Canadian Patent for Method of Using Stem Cells to Treat Non-Ischemic Dilated Cardiomyopathy and Aging-related Frailty in Patients with InflammagingGlobeNewswire
- Longeveron New MRI Biomarker Data Linking Neuroinflammation to Clinical Outcomes in Patients with Mild Alzheimer’s Disease Presented at the Clinical Trials on Alzheimer’s Disease Conference (CTAD 2025)GlobeNewswire
- Longeveron Laromestrocel Data in Alzheimer’s Disease Selected for Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (CTAD 2025)GlobeNewswire
- Longeveron Granted U.S. Patent for Method of Treating Aging-related Frailty in Patients with Inflammaging Using its Proprietary Stem Cell TherapyGlobeNewswire
LGVN
Earnings
- 11/4/25 - Miss
LGVN
Sec Filings
- 11/12/25 - Form 8-K
- 11/4/25 - Form 8-K
- 11/4/25 - Form 10-Q
- LGVN's page on the SEC website